Abrocitinib for atopic dermatitis - Authors' reply

Lancet. 2021 Jan 16;397(10270):196. doi: 10.1016/S0140-6736(21)00037-4.

Authors

Eric L Simpson¹, Thomas Bieber², Jacob P Thyssen³, Hernan Valdez⁴, Ricardo Rojo⁵

Affiliations

¹ Oregon Health & Science University, Portland, OR, USA.
² Department of Dermatology and Allergy, University Hospital, Bonn, Germany.
³ Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
⁴ Pfizer, New York, NY, USA.
⁵ Pfizer, Groton, CT 06340, USA. Electronic address: ricardo.rojo@pfizer.com.

PMID: 33453780
DOI: 10.1016/S0140-6736(21)00037-4

No abstract available

Publication types

Letter
Comment

MeSH terms

Dermatitis, Atopic* / drug therapy
Eczema*
Humans
Pyrimidines
Sulfonamides

Substances

Pyrimidines
Sulfonamides
abrocitinib